

Rationale for revision in Pricing of “Future Varishta Bima” product

We wish to bring to your notice that our Health Product, namely, “Future Varishta Bima”, has undergone revision in its Pricing. The said revision shall be rendered effective on and from 01 March 2024.

You may find the rationale for revision in pricing described below:

- a) To bring the current pricing in line with the experience observed under the various cohorts of the product and align the same to the company’s defined risk appetite.
- b) To avoid any pricing cross subsidization that may have emerged over a period between various cohorts of the product.
- c) To align the pricing to the impact of inflation and other emerging trends since the last filing of the product.